Compare National Beverage Corp. (FIZZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

FIZZ trades at $29.60, down 1.4% with bearish technical signals from moving averages. The company reported flat revenue of $1.2B in 2025 but maintained strong profitability with 36.2% gross margins and 40.1% ROE. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026, though margins compressed to 35% and EPS declined to $0.50. Analyst sentiment is cautious with 50% sell ratings amid concerns about stalled growth and margin pressure from input costs.

The outlook remains challenging with LaCroix volumes declining for four consecutive years and Trump tariffs impacting profitability. While valuation multiples appear reasonable (P/E 15.9, EV/EBITDA 11.3), the lack of clear growth catalysts and negative cash flow trends present headwinds. The $3.25 special dividend provides shareholder return but reduces equity base, highlighting the company's mature market position.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.